- Home
- RPAY vs CAPR Comparison
RPAY vs CAPR Comparison
Compare RPAY & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPAY
- CAPR
- Stock Information
- Founded
- RPAY 2006
- CAPR 2005
- Country
- RPAY United States
- CAPR United States
- Employees
- RPAY N/A
- CAPR N/A
- Industry
- RPAY Business Services
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RPAY Consumer Discretionary
- CAPR Health Care
- Exchange
- RPAY Nasdaq
- CAPR Nasdaq
- Market Cap
- RPAY 387.2M
- CAPR 453.9M
- IPO Year
- RPAY N/A
- CAPR N/A
- Fundamental
- Price
- RPAY $4.79
- CAPR $7.64
- Analyst Decision
- RPAY Buy
- CAPR Strong Buy
- Analyst Count
- RPAY 9
- CAPR 8
- Target Price
- RPAY $8.06
- CAPR $27.13
- AVG Volume (30 Days)
- RPAY 1.3M
- CAPR 3.8M
- Earning Date
- RPAY 08-07-2025
- CAPR 08-06-2025
- Dividend Yield
- RPAY N/A
- CAPR N/A
- EPS Growth
- RPAY N/A
- CAPR N/A
- EPS
- RPAY N/A
- CAPR N/A
- Revenue
- RPAY $309,647,000.00
- CAPR $17,363,588.00
- Revenue This Year
- RPAY N/A
- CAPR $453.92
- Revenue Next Year
- RPAY $8.40
- CAPR N/A
- P/E Ratio
- RPAY N/A
- CAPR N/A
- Revenue Growth
- RPAY 2.26
- CAPR N/A
- 52 Week Low
- RPAY $3.59
- CAPR $3.52
- 52 Week High
- RPAY $10.16
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- RPAY 48.67
- CAPR 38.00
- Support Level
- RPAY $4.84
- CAPR $9.65
- Resistance Level
- RPAY $5.12
- CAPR $11.88
- Average True Range (ATR)
- RPAY 0.16
- CAPR 1.05
- MACD
- RPAY -0.00
- CAPR -0.11
- Stochastic Oscillator
- RPAY 42.61
- CAPR 17.51
About RPAY Repay Holdings Corporation
Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.